Vaxfab Enterp. (542803)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Vaxfab Enterp is precisely the kind of business I would normally walk away from. A trading and distribution company rarely has a durable moat, and the numbers confirm my suspicion. The latest quarter shows ₹16 Cr of sales and a ₹3 Cr net loss—that is roughly an 18% negative margin. Sales growth is minus 65.79%, profit growth is minus 150.55%, and ROCE is a flat 0.00%. This is not a temporary pothole; it is a business losing altitude quickly. A Piotroski F-score of 2 out of 9 tells me the financial health is poor, and promoter holding is not even disclosed, which makes me uncomfortable. At ₹9.95, the stock trades at 2.54 times book value of ₹3.92 and a reported P/E of 153.35. That P/E is meaningless when the most recent quarter is loss-making. Graham would say there is no margin of safety here. The only positive is the tiny ₹9 Cr market cap relative to the quarterly sales run-rate, so a genuine turnaround could produce explosive percentage returns. But that is speculation, not investment. I need evidence: sales stabilisation, narrowing losses, positive operating cash flow, and an F-score moving above 5. Until then, this belongs on the too-hard pile.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer